Market: NMS |
Currency: USD
Address: 221 Crescent Street
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
📈 Apogee Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$116.53
-
Upside/Downside from Analyst Target:
66.43%
-
Broker Call:
28
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2026-05-11
-
EPS Estimate:
-1.13
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Apogee Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2026-05-11 (estimated upcoming) | - |
| 2026-03-02 | -1.03 |
| 2025-11-10 | -1.11 |
| 2025-08-11 | -1.13 |
| 2025-05-12 | -0.95 |
| 2025-03-03 | -1.2 |
| 2024-11-12 | -0.86 |
| 2024-08-12 | -0.6 |
| 2024-05-13 | -0.64 |
| 2024-03-05 | -0.32 |
| 2023-11-13 | -0.51 |
| 2023-08-28 | -3.78 |
📰 Related News & Research
-
Apogee Therapeutics Announces $350 Million Public Offering of 5 Million Shares in Underwriting Agreement with Jefferies, TD Securities, Stifel, and Guggenheim 12137980
March 26, 2026
Apogee Therapeutics, Inc. Announces \$350 Million Public Off...
-
Apogee Therapeutics Reports Positive 52-Week Phase 2 Results for Zumilokibart in Atopic Dermatitis With Durable Efficacy and Infrequent Dosing 13
March 23, 2026
Apogee Therapeutics Announces Positive Phase 2 Results for Z...
-
Apogee Therapeutics Reports 2025 Financial Results and Pipeline Progress for Zumilokibart in Atopic Dermatitis, Asthma, and Expansion Indications 12
March 2, 2026
Apogee Therapeutics Pipeline Progress & Full Year 2025 Finan...
-
Apogee Therapeutics 2025 Annual Report: Pipeline Overview, Strategy, and Clinical Progress in Inflammatory and Immunology Markets
March 2, 2026
Key Highlights from Apogee Therapeutics, Inc. 2025 Annual Re...
🔍 View more Reports
